Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5396517 | PMC |
| http://dx.doi.org/10.1172/jci.insight.94088 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Use of a pulmosphere model to evaluate drug antifibrotic responses in interstitial lung diseases.
Respir Res
March 2023
Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
Background: Interstitial lung diseases (ILD) encompass a heterogenous group of diffuse parenchymal lung disorders characterized by variable degrees of inflammation and fibrosis. Pretherapeutic clinical testing models for such diseases can serve as a platform to test and develop effective therapeutic strategies. In this study, we developed patient derived 3D organoid model to recapitulate the disease process of ILDs.
View Article and Find Full Text PDF3D pulmospheres serve as a personalized and predictive multicellular model for assessment of antifibrotic drugs.
JCI Insight
January 2017
Division of Pulmonary, Allergy, and Critical Care Medicine and.
Idiopathic pulmonary fibrosis (IPF) is a fatal progressive fibrotic lung disease characterized by the presence of invasive myofibroblasts in the lung. Currently, there are only two FDA-approved drugs (pirfenidone and nintedanib) for the treatment of IPF. There are no defined criteria to guide specific drug therapy.
View Article and Find Full Text PDF